There are at least 3 clinical studies that use checkpoint inhibitors such as: phase III trial testing Nivolumab and Iipilimumab—anti-PD-1 and anti-CTLA-4 antibodies, respectively—in patients with recurrent glioblastoma; a phase II trial testing Durvalumab, an anti-PD-L1 antibody, in patients with glioblastoma and a phase II trial testing Pembrolizumab, an anti-PD-1 antibody, with or without Bevacizumab, in patients with recurrent glioblastoma multiform. This evidence concerns the gene CTLA4 and glioblastoma.